SCHEMBL1725970

SCHEMBL1725970

COC(=O)CCN1CCN(C)CC1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.61
TP53 P04637 2/20 0.53
TSHR P16473 2/20 0.50
PAOX Q6QHF9 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489670 0.96 SMN1; SMN2 (0.65) SMN1; SMN2TP53TSHRPAOXL3MBTL1
SCHEMBL1174392 0.96
SCHEMBL28996592 0.88 SMN1; SMN2 (0.57) SMN1; SMN2TP53TSHRL3MBTL1ALDH1A1
SCHEMBL26528338 0.88 PAOX (0.56) SMN1; SMN2TP53TSHRPAOXL3MBTL1
SCHEMBL26528341 0.88 SMN1; SMN2 (0.57) SMN1; SMN2TP53TSHRL3MBTL1ALDH1A1
SCHEMBL5483874 0.87 SMN1; SMN2 (0.61) SMN1; SMN2TP53TSHRL3MBTL1ALDH1A1
SCHEMBL65886 0.87 SMN1; SMN2 (0.61) SMN1; SMN2TSHRL3MBTL1ALDH1A1KDM4E
SCHEMBL16265631 0.87 SMN1; SMN2 (0.53) SMN1; SMN2TP53TSHRPAOXL3MBTL1
SCHEMBL22878472 0.86 SMN1; SMN2 (0.56) SMN1; SMN2TP53TSHRPAOXL3MBTL1
SCHEMBL17284723 0.86 SMN1; SMN2 (0.60) SMN1; SMN2TP53TSHRPAOXL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183616-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2023-09-28 WO disclosed
EP-3145929-B1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS HOFFMANN LA ROCHE (CH) 2021-01-13 EP disclosed
WO-2019034538-A1 SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS UNIVERSITÄT REGENSBURG (DE) 2019-02-21 WO disclosed
US-20170226132-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-08-10 US disclosed
US-20170145020-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-05-25 US disclosed
US-9604984-B2 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2017-03-28 US disclosed
US-20160237086-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-08-18 US disclosed
US-20160185780-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-06-30 US disclosed
US-9346815-B2 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2016-05-24 US disclosed
EP-2403838-B1 COMPOSITIONS CONTAINING AMIDE SURFACTANTS AND METHODS FOR INHIBITING THE FORMATION OF HYDRATE AGGLOMERATES NALCO CO (US) 2016-04-27 EP disclosed
US-20100087338-A1 COMPOSITIONS AND METHODS FOR INHIBITING THE AGGLOMERATION OF HYDRATES US SYNTHETIC CORPORATION 2010-04-08 US disclosed
US-20100087338-A1 COMPOSITIONS AND METHODS FOR INHIBITING THE AGGLOMERATION OF HYDRATES US SYNTHETIC CORPORATION 2010-04-08 US disclosed
US-20100087339-A1 COMPOSITIONS AND METHODS FOR INHIBITING THE AGGLOMERATION OF HYDRATES IN A PROCESS APERGY BMCS ACQUISITION CORP 2010-04-08 US disclosed
US-20100087339-A1 COMPOSITIONS AND METHODS FOR INHIBITING THE AGGLOMERATION OF HYDRATES IN A PROCESS APERGY BMCS ACQUISITION CORP 2010-04-08 US disclosed
US-20080200433-A1 Molecular Chaperone Function Regulator MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-21 US disclosed
US-20080200433-A1 Molecular Chaperone Function Regulator MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-21 US disclosed
US-20070265260-A1 Quinazoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-11-15 US disclosed
US-20070265260-A1 Quinazoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-11-15 US disclosed
US-7294629-B2 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-11-13 US disclosed
US-7294629-B2 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185780-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, JAK1 SMN1; SMN2 3249/4885TP53 4346/4885TSHR 2621/4885
US-20100087339-A1 COMPOSITIONS AND METHODS FOR INHIBITING THE AGGLOMERATION OF HYDRATES IN A PROCESS AQP1, AQP3, AQP4 SMN1; SMN2 4177/4885TP53 406/4885TSHR 4423/4885
US-20160237086-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, FLT3 SMN1; SMN2 3594/4885TP53 735/4885TSHR 3652/4885
US-20100087338-A1 COMPOSITIONS AND METHODS FOR INHIBITING THE AGGLOMERATION OF HYDRATES AQP1, AQP3, ABCB7 SMN1; SMN2 4436/4885TP53 202/4885TSHR 4148/4885
US-20170145020-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, FLT3 SMN1; SMN2 3594/4885TP53 735/4885TSHR 3652/4885
US-20170226132-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, JAK1 SMN1; SMN2 3249/4885TP53 4346/4885TSHR 2621/4885
US-20070265260-A1 Quinazoline derivatives TYK2, ROR1, JAK1 SMN1; SMN2 4784/4885TP53 297/4885TSHR 4548/4885
US-20080200433-A1 Molecular Chaperone Function Regulator HSPBP1, HSF1, HSPH1 SMN1; SMN2 3552/4885TP53 318/4885TSHR 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.